当前，江北区正推进"133"产业集群建设，其高性能铜合金材料、光学反射膜材料等产品市场占有率居 全球前列，还打造了高储能和关键电子材料国家级创新型产业集群等高能级平台。江北区委主要负责人 称，IAAM攻坚方向与区域产业战略高度契合，将借其资源深化全球人才合作，推动产业高质量发展。 IAAM亚太总部已制定五年规划，凸显"产学研用深度融合"特色——重点强化与工业企业联动，既助力 科研人员对接企业需求，又加速成果转化，打通创新链与产业链"最后一公里"，同时还将推进机构建 设、重点项目及国际交流。 会议期间，近120位中外顶尖专家齐聚，江北区解读"人才+科技+产业"政策矩阵，辖区企业与专家精准 对接技术需求，专家团还走访科研院所与企业研讨人才引育与技术转化。 中新网浙江新闻9月26日电 （张斌）25日，以"智汇北岸聚联世界"为主题的国际先进材料协会 （IAAM）首届产业创新发展会议在浙江宁波江北举行，标志着IAAM亚太总部正式落户江北。这一国 际标杆组织的落地，通过"学会协会引才"创新模式，为江北链接全球高端智力资源、推进科创产创融合 注入强劲动力。 活动现场。江北官方 供图 总部位于瑞典的IAAM成立于2010年， ...

邢晓钟对兰石中科在纳米材料技术与资源循环利用融合创新方面取得的成果给予高度评价。他表示，金川集团铜贵公司与兰石中科在前期科研合作中已建 立起坚实的互信基础与协同机制，双方共同推进的工业化试验项目成效显著，为后续产业化落地提供了有力支撑。未来，金川铜贵将持续与兰石中科携 手，在技术研发与原料供应等领域深化合作协同，共同拓展新材料在高端装备制造等领域的应用场景，助力产业链价值提升。 康向京对金川集团及铜贵公司长期以来给予的信任与支持表示衷心感谢。他表示，兰石中科将以此次交流为契机，持续深化与金川铜贵在纳米材料改性、 金属资源循环利用等方向的联合攻关，加快推动科技成果向现实生产力转化，共同打造产学研用深度融合的协同创新典范，为我国新材料产业高质量发展 注入新动能。（乔娅妮） 9月22日，金川集团党委常委、副总经理、金川集团铜贵股份有限公司党委书记、董事长邢晓钟一行到兰石中科参观交流。兰石集团副总经理高峰，兰石 中科董事、总经理康向京，总工程师侯晓刚等陪同接待。 邢晓钟一行参观了兰石中科展厅及纳米材料小试生产线，详细听取了关于公司自主知识产权核心技术、纳米材料制备工艺路线、科技成果转化进展以及重 点项目推进情况的汇报 ...

"我们不培养创业者，我们陪伴创业者成长。"创业营班主任、浙江省数字经济学会常务副会长章丰 介绍说，创业营组建了一支特殊的"陪跑官"团队——除科技型企业家、投资人、科学家导师外，还有萧 山区人才办、经信、科技、科协等部门的相关负责人，为学员提供从政策解读、人才对接到融资路演、 技术合作的全链条服务。 杭州聆为信息技术有限公司创始人、CEO彭程程这几天正忙着备赛。他的光子科学控制系统项目以 总分第二的成绩，从800多个竞争对手中突围，晋级浙江省"火炬杯"创新创业大赛总决赛。 这位曾在美国、德国等地工作多年的科学家，是"浙里"科学家创业营的首期学员之一。"在外资企 业干了10年，技术我熟悉，但如何让项目在市场上找到精准定位，是我在创业营最想学的。"与彭程程 一样，许多手握硬核技术的科学家在创业之初都面临相似难题。 为此，"浙里"科学家创业营应运而生——项目由浙江省科协指导，萧山区科协联合区委人才办、江 南科技城管理局、浙江省数字经济学会共同发起，以"Link & Inspire"（连接与启发）为核心理念，围绕 战略与方向、产品与IP、组织与团队、客户与增长、财务与融资五大模块，构建起"诊断—赋能—陪 跑"闭环培育体 ...

中国制造业的产业升级，离不开基础原材料的不断创新。 2018年，抚顺特钢加入沙钢集团，并引入沙钢集团先进高效管理机制，双方开启了融合发展。如今，公 司已经拥有国内规模最大、国际领先的特冶炉群，具备粗钢产能95万吨、钢材产能70万吨。 以"三高一特"为主的产品格局，广泛应用于航空航天、能源电力、石油化工、交通运输、机械机电、环 保节能等领域。 其中，公司生产的高温合金、超高强度钢产品，不仅保持着较高水平的市场占有率，在国内也占有举足 轻重的位置。 近期，中国上市公司协会联合《21世纪经济报道》等权威媒体，共同发起"我在'十四五'这五年上市公 司在行动"主题宣传活动。 而过去的近五年时间里，抚顺特钢（600399）便坚持"特钢更特"的发展战略目标，重点布局航空航天、 核电、风电等新兴领域，并在高氮高强马氏体不锈钢、超高强度C250钢锭和耐腐蚀合金等多个产品取 得了突破。 仅以高氮高强马氏体不锈钢为例，该产品可以用于制造航空关键零部件、高抛光模具、耐蚀轴承等，不 仅解决了航空关键材料的急需问题，还打破进口垄断、填补国内空白。 在2025年中国冶金科学技术奖评选中，包括高氮高强马氏体不锈钢在内，由抚顺特钢参与、牵头的 ...

Core Insights - Innovation has become the core driving force for the development of companies in the pharmaceutical industry in China, as highlighted by Kangyuan Pharmaceutical's recent semi-annual report for 2025, which shows a revenue of 1.642 billion yuan and a research and development (R&D) investment ratio of 15.02% [1][2] - The company has achieved significant results in innovative R&D, with the approval of a new traditional Chinese medicine product, Yunu Jian granules, and five new drugs entering clinical research, including the world's first peptide inhibitor targeting the CCR8 receptor, KYS2301 gel [1][5] Financial Performance - In the first half of 2025, Kangyuan Pharmaceutical reported a revenue of 1.642 billion yuan, maintaining a high R&D investment ratio of 15.02%, which has shown a steady upward trend over the past three years [2][6] - The R&D team has grown to 782 members, indicating strong talent reserves and investment intensity within the industry [2] R&D Pipeline - The company has a diverse product pipeline with 28 products in preclinical stages, 15 in Phase I, 12 in Phase II, and 8 in Phase III, covering multiple therapeutic areas [2] - Kangyuan Pharmaceutical emphasizes the deep development and value re-engineering of existing products, exploring new indications and upgrading technologies to extend product life cycles [2][6] Strategic Framework - The company has established a unique "industry-university-research-application" integrated R&D system, collaborating closely with top institutions like Nanjing University of Chinese Medicine and the Shanghai Institute of Materia Medica [3] - Kangyuan Pharmaceutical has set up a national key laboratory for the control and intelligent manufacturing of traditional Chinese medicine, addressing key technical challenges in the pharmaceutical process [3] Innovation Achievements - Kangyuan Pharmaceutical leads in the field of traditional Chinese medicine innovation, with 58 new traditional Chinese medicine products, 47 of which are unique varieties [5] - The KYS2301 gel, a global first CCR8 peptide inhibitor, has received clinical trial approval and is intended for the treatment of atopic dermatitis [5] Market Strategy - The company adopts a dual strategy of focusing on traditional Chinese medicine while expanding into chemical and biological drugs, particularly in gynecology, respiratory, and cardiovascular disease areas [6][7] - Kangyuan Pharmaceutical is advancing its internationalization efforts through a dual filing strategy in China and the U.S., marking progress in its global market expansion [6][7] Future Outlook - The years 2025-2026 are expected to be crucial for the company, with key milestones such as the reading of Phase II clinical data for ZX2021 and the potential launch of its first biological drug [7] - The company is also enhancing its smart manufacturing capabilities through digital extraction factories and intelligent formulation workshops to improve cost efficiency and product quality [7]

Core Insights - The conference focused on key technologies related to complex meteorological environments, aiming to promote deep integration of industry, academia, and research [1][2] - The event highlighted the importance of collaboration between educational institutions and industry players in advancing aviation meteorology [2][3] Group 1: Conference Overview - The conference was themed "Integration of Science and Education for Innovation, Collaborative Problem Solving Across the Entire Chain" and took place at the Civil Aviation University of China [1] - It featured multiple expert presentations on topics such as global trends in low-altitude economy, wind tunnel testing for low-altitude vehicles, and applications of complex wind field simulations [3] Group 2: Industry Collaboration - Beijing Puheng Bolian Technology Co., Ltd. donated automatic aviation meteorological observation equipment to support the university's research and teaching efforts [2] - Tianjin Dongteng Technology Development Co., Ltd. signed a cooperation framework agreement with the university and donated a commercial wind tunnel for use [2] Group 3: Institutional Commitment - The university's vice president emphasized its mission to serve the civil aviation sector and the nation, focusing on technological innovation and talent cultivation in air traffic management and meteorology [2] - The successful application of algorithms and the establishment of the wind tunnel are seen as significant steps in supporting national technology development strategies and enhancing the aviation industry cluster in Tianjin [2]

Group 1 - The fourth China (Macau) International High-Quality Consumption Expo and Hengqin World Bay Area Forum focuses on the theme of "Health New Ecology, Bay Area Common Future" [1] - The Health Forum aims to explore the collaborative paths for building a health ecosystem between Guangdong and Macau in terms of systems, research, and industry [1][2] - The Macau government has implemented policies to promote the standardization and internationalization of traditional Chinese medicine (TCM), laying a solid foundation for the health industry [2] Group 2 - The Macau Drug Regulatory Authority has a special licensing system for drugs, allowing for the import of unregistered drugs in emergencies to meet clinical needs [3] - Macau has multiple advantages for developing the health industry, including policy, regional, research, registration, tourism, and market advantages [3] Group 3 - The forum featured discussions on cutting-edge topics such as cell technology, tissue regeneration, and brain disease repair, highlighting the potential of stem cell therapies [4] - The market for neuroacid, derived from the seven-angle maple, is significant due to its high purity and current sourcing difficulties from deep-sea fish oil [4] Group 4 - A roundtable discussion focused on cross-border integration in the health sector, emphasizing the need for collaboration between research, technology, and international cooperation [5] - Strategic cooperation agreements were signed between organizations to promote technological innovation and result transformation in the TCM health industry [5][6]

Core Insights - The "Optics Valley" has become a hub for young talent in innovation and entrepreneurship, attracting around 2 million young individuals, with over 70% being under 35 years old [1][5][6] - The "Optics Valley Youth Innovation Park" has gathered 254 hard-tech companies, providing comprehensive support including funding, technology, and public services [5][6] - The park has facilitated over 2 billion yuan in financing and loans for startups, helping to create more than 2,500 jobs [6][8] Group 1: Innovation Ecosystem - The park is designed as a "tropical rainforest" style innovation ecosystem, fostering collaboration between universities, research institutions, and enterprises [7][8] - The park's structure includes incubation spaces and acceleration zones, tailored to the growth stages of startups [5][6] - The establishment of the Wuhan Industrial Innovation Development Research Institute aims to support projects with high technical maturity and connect them with industry resources [6][7] Group 2: Success Stories - Companies like QianDa Intelligent have successfully secured angel funding for technology iteration and market expansion, breaking foreign technology monopolies [5][6] - The founder of JingZhen Technology, a Tsinghua University PhD, has established partnerships with medical institutions to integrate AI with healthcare [7] - The Wuhan Industrial Innovation Development Research Institute has incubated over 900 technology achievements and 400 tech companies within three years [7][8] Group 3: Policy and Future Directions - Continuous policy innovation is essential to address challenges faced by young entrepreneurs and optimize institutional support [8] - Emphasis on deep integration of industry, academia, and research to bridge the gap between university outputs and enterprise needs [8] - A focus on providing comprehensive support for talent throughout their career lifecycle to enhance retention and development advantages [8]

宝鸡市相关负责人表示，秦创原（宝鸡）产业创新研究院是宝鸡市重点布局的新型研发机构，是宝 鸡市深化教育科技人才体制机制一体改革、推动产教融合的生动实践，是政校企协同创新的重要结晶。 该研究院的成立，将为全市科技单位及部门、宝鸡文理学院、重点产业链企业技术创新和融合发展提供 有效路径和重要平台。 据了解，秦创原（宝鸡）产业创新研究院将聚焦宝鸡市六大优势产业集群和重点产业链，以需求牵 引创新，全力破解科技成果转化"最后一公里"难题，积极探索产学研用深度融合新路径，"种"好教育科 技人才一体改革"试验田"，大力改革机制促创新，汇聚优势力量促创新，加大人才和智力供给，开放技 术场景与实践平台。（记者：李静茹） 日前，秦创原（宝鸡）产业创新研究院揭牌，落户中国石油集团宝石管业有限公司（以下简称"宝 石管业"）。该研究院的成立旨在聚焦区域产业需求，构建产学研用深度融合的创新体系，通过宝鸡市 科技局、宝鸡文理学院、宝石管业三方协同创新，充分发挥政策资金支持、高质量人才和智力供给、开 放技术场景与实践平台作用，进一步提升科技创新能级，为宝鸡新型工业化建设提供更大支撑。 宝鸡作为西部工业重镇、国家创新型城市和秦创原"两链"融合示 ...

Group 1 - The "Oxford-Cambridge-National University of Singapore Elite Talent Wuhan Tour" event was launched in Wuhan, bringing together 28 doctoral and postdoctoral researchers from top universities to connect with over 40 key employers in the city [1][4] - The participating researchers have educational backgrounds from developed countries and are specialized in fields such as biomedical science, electronic information, artificial intelligence, and materials science, which are critical to Wuhan's key industries [1][4] - The event aims to create a bridge for elite talents from overseas to connect with local enterprises, focusing on deep integration of industry, academia, and research [4] Group 2 - Wuhan is highlighted for its strong industrial foundation, favorable talent policies, and livable environment, particularly in the optoelectronics sector, which aligns well with the research interests of the participants [4] - Key companies such as Dongfeng Motor Corporation, Fenghuo Communication, and Changfei Optical Fiber engaged in in-depth discussions with overseas scholars to showcase Wuhan's industrial advantages and job opportunities [4] - The event includes a three-day in-depth visit to showcase Wuhan's industrial strength, innovation ecosystem, and talent development environment, featuring visits to leading companies and research institutions [4]